Cargando…
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
This study was performed with the aim of discovering the characteristics and survival of patients with metastatic renal carcinoma who undergo immunotherapy with an Interleukin 2 based regimen. One hundred and eighty-one patients with metastatic renal carcinoma were referred to our institute from Oct...
Autores principales: | Philip, T., Negrier, S., Lasset, C., Coronel, B., Bret, M., Blay, J. Y., Merrouche, Y., Carrie, C., Kaemmerlen, P., Chauvin, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968726/ https://www.ncbi.nlm.nih.gov/pubmed/8217594 |
Ejemplares similares
-
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
por: Négrier, S., et al.
Publicado: (1992) -
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
por: Bain, C., et al.
Publicado: (1997) -
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994) -
Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.
por: Blay, J. Y., et al.
Publicado: (1993) -
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)